Literature DB >> 16531550

Going with the flow: methotrexate, adenosine, and blood flow.

B N Cronstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16531550      PMCID： PMC1798096          DOI： 10.1136/ard.2005.049601

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  32 in total

1.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Authors:  Lars Klareskog; Désirée van der Heijde; Julien P de Jager; Andrew Gough; Joachim Kalden; Michel Malaise; Emilio Martín Mola; Karel Pavelka; Jacques Sany; Lucas Settas; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad; Marie Sanda
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

2.  The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.

Authors:  S L Morgan; J E Baggott; W H Vaughn; P K Young; J V Austin; C L Krumdieck; G S Alarcón
Journal:  Arthritis Rheum       Date:  1990-01

3.  Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells.

Authors:  B N Cronstein; M A Eberle; H E Gruber; R I Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  Turnover of adenosine in plasma of human and dog blood.

Authors:  G H Möser; J Schrader; A Deussen
Journal:  Am J Physiol       Date:  1989-04

5.  Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis.

Authors:  L M Buckley; P M Vacek; S M Cooper
Journal:  J Rheumatol       Date:  1990-09       Impact factor: 4.666

6.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.

Authors:  H J Williams; R F Willkens; C O Samuelson; G S Alarcón; M Guttadauria; C Yarboro; R P Polisson; S R Weiner; M E Luggen; L M Billingsley
Journal:  Arthritis Rheum       Date:  1985-07

7.  The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis.

Authors:  Sarah L Morgan; Robert A Oster; Jeannette Y Lee; Graciela S Alarcón; Joseph E Baggott
Journal:  Arthritis Rheum       Date:  2004-10

8.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

9.  The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine.

Authors:  G Nesher; T L Moore
Journal:  Arthritis Rheum       Date:  1990-07

10.  Efficacy of low-dose methotrexate in rheumatoid arthritis.

Authors:  M E Weinblatt; J S Coblyn; D A Fox; P A Fraser; D E Holdsworth; D N Glass; D E Trentham
Journal:  N Engl J Med       Date:  1985-03-28       Impact factor: 91.245
View more
  10 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen.

Authors:  Anand Narayan Malaviya
Journal:  Clin Rheumatol       Date:  2016-09-06       Impact factor: 2.980

Review 3.  Resolution of inflammation: state of the art, definitions and terms.

Authors:  Charles N Serhan; Sue D Brain; Christopher D Buckley; Derek W Gilroy; Christopher Haslett; Luke A J O'Neill; Mauro Perretti; Adriano G Rossi; John L Wallace
Journal:  FASEB J       Date:  2007-02       Impact factor: 5.191

4.  Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.

Authors:  Zhiwei Lin; Jianyi Niu; Yifan Xu; Lijie Qin; Jiabin Ding; Luqian Zhou
Journal:  J Med Virol       Date:  2021-12-13       Impact factor: 20.693

5.  Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment.

Authors:  Edyta Majorczyk; Andrzej Pawlik; Daria Gendosz; Piotr Kuśnierczyk
Journal:  BMC Musculoskelet Disord       Date:  2014-07-28       Impact factor: 2.362

6.  Serum Adenosine Deaminase Level is High But Not Related with Disease Activity Parameters in Patients with Rheumatoid Arthritis.

Authors:  Gülseren Demir; Pınar Borman; Figen Ayhan; Tuba Ozgün; Ferda Kaygısız; Gulsen Yilmez
Journal:  Open Rheumatol J       Date:  2014-09-12

7.  Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients.

Authors:  S A Owen; S L Hider; P Martin; I N Bruce; A Barton; W Thomson
Journal:  Pharmacogenomics J       Date:  2012-03-27       Impact factor: 3.550

8.  Human T-lymphotropic virus 1 neurologic disease.

Authors:  Abelardo Araújo; Marco Antonio Lima; Marcus Tulius T Silva
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.972

Review 9.  Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome.

Authors:  Steven Dudics; David Langan; Rakeshchandra R Meka; Shivaprasad H Venkatesha; Brian M Berman; Chun-Tao Che; Kamal D Moudgil
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

10.  Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model.

Authors:  Zachary L Taylor; Lauren E Thompson; Heather Bear; Tomoyuki Mizuno; Alexander A Vinks; Laura B Ramsey
Journal:  Clin Transl Sci       Date:  2021-06-30       Impact factor: 4.689
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.